Activation of the STAT3 Signaling Pathway Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP
Authors:
- Xin HuangXHXin Huang
- Bin MengBMBin Meng
- Javeed IqbalJIJaveed Iqbal
- B. Belinda DingBDB. Belinda Ding
- Anamarija M. PerryAPAnamarija M. Perry
- Wenfeng CaoWCWenfeng Cao
- Lynette M. SmithLSLynette M. Smith
- Chengfeng BiCBChengfeng Bi
- Chunsun JiangCJChunsun Jiang
- Timothy C. GreinerTGTimothy C. Greiner
- Dennis D. WeisenburgerDWDennis D. Weisenburger
- Lisa RimszaLRLisa Rimsza
- 20 December 2013
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (36) , 4520-4528
Abstract
Purpose: We previously reported that constitutive STAT3 activation is a prominent feature of the activated B-cell subtype of diffuse large B-cell lymphomas (ABC-DLBCL). In this study, we investigated whether STAT3 activation can risk stratify patients with DLBCL. Patients and Methods: By an immunohistochemical method, we investigated phosphotyrosine STAT3 (PY-STAT3) expression from 185 patients with DLBCL treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone). Cell line-based siRNA experiments were also performed to generate an 11-gene, PY-STAT3 activation signature, which was used to study a previously published cohort of 222 patients with DLBCL. The STAT3 activation status determined by these two methods and by STAT3 mRNA levels were then correlated with survival. Results: PY-STAT3 was detected in 37% of DLBCL and enriched in ABC-DLBCL cases (P = .03). PY-STAT3 positivity significantly correlated with poor overall survival (OS; P = .01) and event-free survival (EFS; P = .006). Similar observations were made for high levels of STAT3 mRNA. In multivariable analysis, PY-STAT3 status (P = .02), International Prognostic Index (P = .02), and BCL2 expression (P = .046) were independent prognosticators of OS in this cohort. Among the cell-of-origin subgroups, PY-STAT3 was associated with poor EFS among non–germinal center B-cell DLBCL cases only (P = .027). Similarly, the 11-gene STAT3 activation signature correlated with poor survival in the entire DLBCL cohort (OS, P < .001; EFS, P < .001) as well as the ABC-DLBCL subgroup (OS, P = .029; EFS, P = .025). Conclusion: STAT3 activation correlated with poor survival in patients with DLBCL treated with R-CHOP, especially those with tumors of the ABC-DLBCL subtype.Keywords
This publication has 43 references indexed in Scilit:
- BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and RituximabClinical Cancer Research, 2011
- Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapyLeukemia, 2011
- A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High AccuracyClinical Cancer Research, 2009
- Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3Blood, 2008
- Stromal Gene Signatures in Large-B-Cell LymphomasNew England Journal of Medicine, 2008
- Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathwaysProceedings of the National Academy of Sciences, 2008
- Validating Stat3 in cancer therapyNature Medicine, 2005
- Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic targetNature Medicine, 2005
- Tissue-Specific Autoregulation of the stat3 Gene and Its Role in Interleukin-6-Induced Survival Signals in T CellsMolecular and Cellular Biology, 2001
- Epidemiology of the non-Hodgkin’s lymphomas: Distributions of the major subtypes differ by geographic locationsAnnals of Oncology, 1998